![](/images/graphics-bg.png)
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Joint Authors
Coate, Bruce
Kakuda, Thomas
Vis, Peter
Sekar, Vanitha
Anderson, David
Mrus, Joseph
De La Rosa, Guy
Ryan, Robert
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-03-21
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Objectives.
Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race.
Methods.
Patients received darunavir/ritonavir 600/100mg twice daily plus other antiretrovirals, which could include etravirine 200mg twice daily.
Population pharmacokinetics for darunavir and etravirine were determined over 48 weeks and relationships assessed with virologic response and safety.
Rich sampling for darunavir, etravirine, and ritonavir was collected in a substudy at weeks 4, 24, and 48.
Results.
Pharmacokinetics were estimated in 376 patients for darunavir and 190 patients for etravirine.
Median darunavir AUC12h and C0h were 60,642ng·h/mL and 3624ng/mL, respectively; and for etravirine were 4183ng · h/mL and 280ng/mL, respectively.
There were no differences in darunavir or etravirine AUC12h or C0h by sex or race.
Age, body weight, or use of etravirine did not affect darunavir exposure.
No relationships were seen between darunavir pharmacokinetics and efficacy or safety.
Patients with etravirine exposure in the lowest quartile generally had lower response rates.
Rich sampling showed no time-dependent relationship for darunavir, etravirine, or ritonavir exposure over 48 weeks.
Conclusions.
Population pharmacokinetics showed no relevant differences in darunavir or etravirine exposure by assessed covariates.
Lower etravirine exposures were associated with lower response rates.
American Psychological Association (APA)
Kakuda, Thomas& Sekar, Vanitha& Vis, Peter& Coate, Bruce& Ryan, Robert& Anderson, David…[et al.]. 2012. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-452937
Modern Language Association (MLA)
Kakuda, Thomas…[et al.]. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-452937
American Medical Association (AMA)
Kakuda, Thomas& Sekar, Vanitha& Vis, Peter& Coate, Bruce& Ryan, Robert& Anderson, David…[et al.]. Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Research and Treatment. 2012. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-452937
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-452937